InspireMD

OverviewSuggest Edit

InspireMD was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which it both manufactures and commercializes.
Today, InspireMD is a global company headquartered in Boston, MA. InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection by providing a superior solution to the key clinical issues of vascular procedures.

TypePublic
Founded2005
HQTel Aviv-Yafo, ILMap
Websiteinspiremd.com

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2021)48
Revenue (FY, 2020)$2.5 M(-33%)
Share Price (Apr 2021)$0.6(-1%)
Cybersecurity ratingDMore

Key People/Management at InspireMD

Marvin Slosman

Marvin Slosman

Chief Executive Officer & Director
Paul Stuka

Paul Stuka

Chairman of the Board
Craig Shore

Craig Shore

Chief Financial Officer
Michael Berman

Michael Berman

Director
Gary Roubin

Gary Roubin

Director
Show more

InspireMD Office Locations

InspireMD has offices in Tel Aviv-Yafo and Winsen (Luhe)
Tel Aviv-Yafo, IL (HQ)
4 Menorat HaMa'or St
Winsen (Luhe), DE
16 Boschstraße
Show all (2)

InspireMD Financials and Metrics

InspireMD Revenue

Embed Graph
View revenue for all periods
InspireMD's revenue was reported to be $2.49 m in FY, 2020
USD

Revenue (FY, 2020)

2.5m

Gross profit (FY, 2020)

83.0k

Gross profit margin (FY, 2020), %

3.3%

Net income (FY, 2020)

(10.5m)

EBIT (FY, 2020)

(10.4m)

Market capitalization (7-Apr-2021)

74.8m

Closing stock price (7-Apr-2021)

0.6

Cash (31-Dec-2020)

12.6m

EV

63.1m
InspireMD's current market capitalization is $74.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.0m2.1m3.1m2.8m2.3m1.9m2.8m3.6m3.7m2.5m

Revenue growth, %

(26%)(18%)

Cost of goods sold

3.0m1.4m1.4m2.0m2.6m1.8m2.2m2.6m3.0m2.4m

Gross profit

3.0m694.0k1.7m784.0k(296.0k)102.0k585.0k995.0k756.0k83.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.0m2.0m1.1m1.4m1.5m1.6m1.5m193.0k273.0k477.0k685.0k632.0k563.0k540.0k469.0k569.0k640.0k718.0k1.0m1.0m769.0k415.0k1.4m939.0k1.0m313.0k

Cost of goods sold

640.0k801.0k574.0k547.0k674.0k750.0k625.0k584.0k349.0k514.0k897.0k543.0k497.0k478.0k438.0k495.0k493.0k565.0k714.0k726.0k571.0k488.0k912.0k811.0k739.0k433.0k

Gross profit

400.0k1.2m564.0k803.0k840.0k802.0k857.0k(391.0k)(76.0k)(37.0k)(212.0k)89.0k66.0k62.0k31.0k74.0k147.0k153.0k293.0k277.0k198.0k(73.0k)442.0k128.0k295.0k(120.0k)

Gross profit Margin, %

38%60%50%59%55%52%58%(203%)(28%)(8%)(31%)14%12%11%7%13%23%21%29%28%26%(18%)33%14%29%(38%)
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

5.1m10.3m17.5m3.3m7.5m3.7m9.4m5.5m12.6m

Accounts Receivable

2.3m1.8m1.9m405.0k643.0k716.0k823.0k476.0k

Prepaid Expenses

72.0k93.0k141.0k75.0k62.0k81.0k87.0k334.0k

Inventories

2.1m1.7m1.6m753.0k500.0k533.0k1.1m1.2m1.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.1m7.5m3.4m5.4m2.5m11.4m13.7m9.0m5.0m13.2m9.8m6.5m2.0m885.0k10.5m8.6m6.9m4.8m4.6m6.4m11.2m5.8m4.8m7.2m3.1m13.9m

Accounts Receivable

614.0k1.8m2.0m1.3m2.1m2.1m1.5m493.0k397.0k719.0k728.0k546.0k432.0k542.0k471.0k451.0k538.0k754.0k916.0k710.0k464.0k861.0k796.0k856.0k416.0k

Prepaid Expenses

71.0k103.0k89.0k94.0k91.0k144.0k110.0k215.0k138.0k109.0k76.0k62.0k41.0k107.0k21.0k73.0k109.0k53.0k71.0k145.0k66.0k44.0k155.0k63.0k40.0k

Inventories

1.5m1.9m2.0m2.0m2.0m1.4m1.3m1.5m1.7m1.8m1.2m1.1m511.0k387.0k365.0k329.0k429.0k576.0k517.0k637.0k816.0k1.4m1.2m1.3m1.2m1.4m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(14.7m)(7.1m)(9.3m)(25.1m)(15.6m)(8.5m)(8.4m)(7.2m)(10.0m)(10.5m)

Depreciation and Amortization

89.0k69.0k188.0k263.0k241.0k191.0k178.0k152.0k158.0k151.0k

Inventories

(261.0k)317.0k(331.0k)1.2m253.0k(33.0k)(601.0k)(102.0k)(179.0k)

Accounts Payable

(371.0k)(291.0k)737.0k(659.0k)(397.0k)106.0k(290.0k)584.0k(283.0k)(410.0k)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.1m)(6.4m)(3.1m)(9.4m)(14.3m)(3.9m)(6.0m)(13.5m)(20.3m)(5.2m)(9.1m)(12.7m)(2.6m)(4.6m)(6.6m)(2.6m)(4.9m)(6.9m)(2.4m)(3.0m)(5.0m)(3.2m)(5.4m)(7.5m)(2.0m)(4.5m)

Depreciation and Amortization

38.0k52.0k34.0k95.0k146.0k50.0k56.0k122.0k181.0k75.0k135.0k195.0k48.0k95.0k143.0k42.0k84.0k127.0k41.0k79.0k115.0k35.0k73.0k114.0k51.0k88.0k

Inventories

(51.0k)(233.0k)(238.0k)201.0k250.0k79.0k(89.0k)174.0k695.0k843.0k242.0k366.0k388.0k171.0k71.0k(76.0k)16.0k(104.0k)(283.0k)(313.0k)(84.0k)(149.0k)34.0k(166.0k)

Accounts Payable

(340.0k)(541.0k)(481.0k)60.0k(65.0k)19.0k(218.0k)(94.0k)(75.0k)(244.0k)(418.0k)(75.0k)(59.0k)686.0k(103.0k)(267.0k)(145.0k)(216.0k)184.0k148.0k128.0k(57.0k)(311.0k)(242.0k)(84.0k)(188.0k)
show all
USDQ2, 2011

Financial Leverage

1.6 x
Show all financial metrics

InspireMD Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

Learn more about our premium products
SecurityScorecard logo

InspireMD Online and Social Media Presence

InspireMD's Trends

Embed Graph

InspireMD News and Updates

March 22, 2021

InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders

TEL AVIV, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvin Slosman regardin…
March 09, 2021

InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results

Management to host investor conference call today, March 9, at 8:30am ET Management to host investor conference call today, March 9, at 8:30am ET
March 02, 2021

InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update

Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET
February 24, 2021

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract…
February 09, 2021

InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States

TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical resear…
February 04, 2021

InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering

TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, t…
Show more

 InspireMD Frequently Asked Questions

  • When was InspireMD founded?

    InspireMD was founded in 2005.

  • Who are InspireMD key executives?

    InspireMD's key executives are Marvin Slosman, Paul Stuka and Craig Shore.

  • How many employees does InspireMD have?

    InspireMD has 48 employees.

  • What is InspireMD revenue?

    Latest InspireMD annual revenue is $2.5 m.

  • What is InspireMD revenue per employee?

    Latest InspireMD revenue per employee is $51.8 k.

  • Who are InspireMD competitors?

    Competitors of InspireMD include Elanix Biotechnologies, 19Labs and Biovotion.

  • Where is InspireMD headquarters?

    InspireMD headquarters is located at 4 Menorat HaMa'or St, Tel Aviv-Yafo.

  • Where are InspireMD offices?

    InspireMD has offices in Tel Aviv-Yafo and Winsen (Luhe).

  • How many offices does InspireMD have?

    InspireMD has 2 offices.